Intriguingly, despite the state‐of‐the‐art pharmaceutical strategies, such as the uses of angiotensin‐converting enzyme inhibitor (ACEI), angiotensin II type I receptor blockade (ARB), and direct renin inhibitor (DRI), as well as good education, and renewed guideline for CKD precision management, progressive deterioration of residual renal function in the setting of CKD is commonly encountered, as a subsequence of leading to the adverse development of end‐stage renal disease (ESRD).23, 24, 25, 26, 27, 28. Here, ACE is linked to chronic kidney disease.